Navigation Links
Dr. Jane L. Delgado Appointed By Senate Majority Leader to Board of National Urban Air Toxics Research Center
Date:12/8/2008

Center Named in Memory of Leading Health Advocate Congressman Mickey Leland

WASHINGTON, Dec. 8 /PRNewswire-USNewswire/ -- U.S. Senate Majority Leader Harry Reid today announced the appointment of Jane L. Delgado, Ph.D., M.S. to the Board of Directors of the Mickey Leland National Urban Air Toxics Research Center (NUATRC), the Congressionally mandated non-profit public/private research organization. She becomes the first Hispanic and first Latina to be appointed to this prestigious board. Dr. Delgado is the President and CEO of the National Alliance for Hispanic Health, the nation's leading science and community-based Hispanic health advocacy and service organization.

"I am honored by Senator Reid's appointment and look forward to joining the respected and accomplished Mickey Leland National Urban Air Toxics Research Center," said Dr. Delgado. "The Leland Center has helped uncover human health effects caused by exposure to air toxics and has moved the nation forward in securing the promise of clean and healthy air to breathe. I am particularly honored by this appointment because the Center helps fulfill Congressman Mickey Leland's legacy as a champion for the rights of all people to clean air and good health. It was my great blessing to have worked with Congressman Leland before his untimely death and I look forward to supporting the work of the Leland Center in fulfilling his vision of a better world."

Dr. Delgado previously served on the Environmental Protection Agency's (EPA) Clean Air Act Advisory Committee and made environmental health a program focus of the Alliance in the 1980s. Among other programs she founded the Alliance's Health and Environment Action Network (HEAN), a remarkable national effort connecting communities with cutting-edge mobile air and water monitoring technology. Dr. Delgado is the author of the award-winning book ¡SALUD! A Latina's Guide to Total Health and most rec
'/>"/>

SOURCE National Alliance for Hispanic Health
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
2. William Moore Appointed to IRIDEX Board of Directors
3. Roy Jakobs Appointed Elsevier Managing Director, A&G Sales and Customer Marketing
4. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
5. James B. Hawkins Appointed to IRIDEX Board of Directors
6. Bryan R. Rogers Appointed President of Far West Division
7. Theodore A. Boutacoff Appointed President & CEO of IRIDEX
8. Catholic Health Association Disappointed by Failure to Override SCHIP Veto
9. Steven M. Safyer, MD, Appointed President and CEO of Montefiore Medical Center
10. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
11. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Delayed First Visit to Dentist Can Affect Childrens Lifelong Oral Health 58581 1Delayed First Visit to Dentist Can Affect Childrens Lifelong Oral Health 58581 2Sleep Center at Baylor Dallas One of Select Centers in North Texas to Receive Accreditation 58576 1Sleep Center at Baylor Dallas One of Select Centers in North Texas to Receive Accreditation 58576 2United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 5114 1United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 5114 2United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 5114 3